DDInter1031 DDInter210
Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as ledipasvir. More specifically, ledipasvir is an inhibitor of the Hepatitis C Virus (HCV) Non-Structural Protein 5A (NS5A), which is required for viral RNA replication and assembly of HCV virions. Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of NS5A which is required
Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Binimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Delavirdine
Binimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Binimetinib {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Binimetinib {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Binimetinib may lead to a major life threatening interaction when taken with Ramucirumab
Binimetinib may lead to a major life threatening interaction when taken with Zanubrutinib